Up­dat­ed: Lil­ly's rev­enues rise 28% in Q2 thanks to surge in de­mand for di­a­betes drug Moun­jaro

Eli Lil­ly said its rev­enues in the sec­ond quar­ter jumped 28% year-over-year due to growth from its type 2 di­a­betes drug Moun­jaro, breast can­cer treat­ment Verzenio, re­cent­ly ex­pand­ed di­a­betes med­i­cine Jar­diance and the au­toim­mune bi­o­log­ic Taltz.

Moun­jaro reeled in about $980 mil­lion in the three-month stretch, the drug­mak­er said Tues­day morn­ing, com­ing in well above the Wall Street con­sen­sus of $740 mil­lion, TD Cowen an­a­lyst Steve Scala wrote in a note.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER